Matches in Wikidata for { <http://www.wikidata.org/entity/Q99636179> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q99636179 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q99636179 description "scientific article published on 28 August 2020" @default.
- Q99636179 description "wetenschappelijk artikel" @default.
- Q99636179 description "наукова стаття, опублікована 28 серпня 2020" @default.
- Q99636179 name "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 name "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 type Item @default.
- Q99636179 label "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 label "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 prefLabel "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 prefLabel "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial S" @default.
- Q99636179 P1433 Q99636179-7B2C7254-0991-471B-826E-751633FA21AD @default.
- Q99636179 P1476 Q99636179-80A6B0A5-38E0-43A6-A094-BE2F8C68A467 @default.
- Q99636179 P2093 Q99636179-00AEE8EA-F18E-49DF-BCDC-384CC036543F @default.
- Q99636179 P2093 Q99636179-1E5C89F0-E394-47F2-955A-E3A30E3E26C2 @default.
- Q99636179 P2093 Q99636179-1F7BFA51-C828-49AD-B94B-76562027D504 @default.
- Q99636179 P2093 Q99636179-20CE10E7-7DD3-4B2B-9609-01412675901A @default.
- Q99636179 P2093 Q99636179-7B82984E-54EA-40B8-89CB-7A520ACD5404 @default.
- Q99636179 P2093 Q99636179-807CC261-590C-4881-9EC3-424A0D962559 @default.
- Q99636179 P2093 Q99636179-8CB3688F-FC18-460C-AEAB-24E91C6A3BDD @default.
- Q99636179 P2093 Q99636179-95149577-FFAC-4C47-BA70-D28B11D58649 @default.
- Q99636179 P2093 Q99636179-C41BD865-5C92-4613-BBC2-CC5FEC4D2F5F @default.
- Q99636179 P2093 Q99636179-D39E8F33-DA97-4FE1-AB9B-03D54CC7573A @default.
- Q99636179 P2093 Q99636179-F8FB3A8C-3D65-4E04-9C4F-05F130017F1C @default.
- Q99636179 P2093 Q99636179-FB35534E-2EEA-4201-AAF0-73E9AF17F411 @default.
- Q99636179 P31 Q99636179-00530E47-5709-481A-893F-5E3010A8FF9E @default.
- Q99636179 P356 Q99636179-539BD84C-FAF4-40A0-A1E5-C11487075CB0 @default.
- Q99636179 P577 Q99636179-54524847-5B66-4E25-9455-E70FCB3CB9F0 @default.
- Q99636179 P698 Q99636179-595C952B-9D47-49CF-92BA-98F4A9FABBF6 @default.
- Q99636179 P921 Q99636179-25DB8420-283D-4B35-A228-24C700BD298D @default.
- Q99636179 P921 Q99636179-821FC023-6FD2-4EA6-A648-12FA2D9B8B62 @default.
- Q99636179 P921 Q99636179-8C963E6C-0D2C-4FA0-8655-F380803110B5 @default.
- Q99636179 P921 Q99636179-ED4087E1-5695-41C1-A693-897B8D526F35 @default.
- Q99636179 P356 J.EURURO.2020.08.024 @default.
- Q99636179 P698 32868138 @default.
- Q99636179 P1433 Q15763991 @default.
- Q99636179 P1476 "Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses" @default.
- Q99636179 P2093 "Aude Fléchon" @default.
- Q99636179 P2093 "Brigitte Laguerre" @default.
- Q99636179 P2093 "Christian Pfister" @default.
- Q99636179 P2093 "Florence Joly" @default.
- Q99636179 P2093 "Gwenaelle Gravis" @default.
- Q99636179 P2093 "Laurent Guy" @default.
- Q99636179 P2093 "Michel Soulié" @default.
- Q99636179 P2093 "Nicolas Mottet" @default.
- Q99636179 P2093 "Stéphane Culine" @default.
- Q99636179 P2093 "VESPER Trial Investigators" @default.
- Q99636179 P2093 "Valentin Harter" @default.
- Q99636179 P2093 "Yves Allory" @default.
- Q99636179 P31 Q13442814 @default.
- Q99636179 P356 "10.1016/J.EURURO.2020.08.024" @default.
- Q99636179 P577 "2020-08-28T00:00:00Z" @default.
- Q99636179 P698 "32868138" @default.
- Q99636179 P921 Q18936 @default.
- Q99636179 P921 Q282629 @default.
- Q99636179 P921 Q412415 @default.
- Q99636179 P921 Q422232 @default.